How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,770 results for

Cerebral Aneurysm

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5281. Effects of a NeuroAD System, for the Treatment of Alzheimer Disease

for receiving TMS treatment according to a TMS questionnaire Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants in mouth Cardiac pacemakers Implanted medication pumps Intracardiac lines Significant heart disease Currently taking medication that lower the seizure threshold Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you (...) Library of Medicine related topics: related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: NeuroAD NeuroAd Treatment, synchronized TMS and cognitive training stimulation Device: NeuroAD Synchronized TMS and cognitive stimulation to 6 brain areas. Other Name: NICE Sham Comparator: Sham TMS+Cog Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers

2014 Clinical Trials

5282. Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine

Criteria for Transcatheter closure group: Subjects with intracardiac thrombus or tumor Subjects who have an acute or recent (within 6 months) myocardial infarction or unstable angina Subjects with left ventricular aneurysm or akinesis Subjects with atrial fibrillation/atrial flutter (chronic or intermittent) Subjects with another source of right to left shunt identified at baseline, including an atrial septal defect and/or fenestrated septum Subjects with contraindication to aspirin or Clopidogrel (...) terms Migraine Disorders Foramen Ovale, Patent Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Heart Septal Defects, Atrial Heart Septal Defects Heart Defects, Congenital Cardiovascular Abnormalities Cardiovascular Diseases Heart Diseases Congenital Abnormalities

2014 Clinical Trials

5283. The Pathogenesis of Terson Syndrome and the Role of CSF Tau / Amyloid-ß 40 and 42 in Patients With Aneurysmatic Subarachnoid Hemorrhage

subarachnoid hemorrhage. Our two hypotheses are as follows: The incidence of Terson syndrome correlates with the initial intracranial opening pressure (measured with extra ventricular drain) The CSF-biomarkers correlate with the outcome assessed at discharge, 3-, 6- and 12-months postictally using Glasgow-Outcome-Scale-Extended (GOSE) and Euro-Qol-5 as well as with complications related to aneurysmatic subarachnoid hemorrhage such as cerebral vasospasm, delayed cerebral ischemia and re-bleed. Condition (...) (group A: Terson syndrome positive, group B: Terson syndrome negative). CSF samples from external ventricular drainages are obtained at day 0, 2 and 6 and concentration of tau-protein and amyloid-β 40 and 42 are determined and correlated to secondary outcome measures such as delayed cerebral ischemia, clinical vasospasm, re-bleed, necessity for surgical intervention secondary to raised intracranial pressure or CSF-diversion. Outcome in terms of Glasgow-Outcome-Scale-Extended and Euro-Qol-5

2014 Clinical Trials

5284. Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries

procedure. Planned endovascular or surgical procedure 30 days after the index procedure. Lesion in the contralateral limb requiring intervention during the index procedure or within 30 days of the index procedure. Subjects with active infections whether they are being currently treated or not. Hemodialysis or GFR <30 mL/min or creatinine level >2.5mg/dL. Evidence or history of intracranial or gastrointestinal bleeding, intracranial aneurysm, myocardial infarction or stroke within the past 2 months (...) . Evidence or history of aneurysmal target vessel within the past 2 months. History of severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days. Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated. Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is contraindicated. History of heparin-induced thrombocytopenia (HIT). Uncorrectable bleeding diathesis, platelet dysfunction

2014 Clinical Trials

5285. Predictors of Antidepressant Response

of an implant, pacemaker or pacemaker wires, open heart surgery, artificial heart valve, brain aneurysm surgery, middle ear implant, hearing aid, braces or extensive dental work, cataract surgery or lens implant, implanted mechanical or electrical device, or artificial limb or joint No metallic object in their body (such as braces) or have a history of foreign metallic object in the body such as bullets, BB's, pellets, shrapnel, or other metal fragments Contacts and Locations Go to Information from (...) Go to Brief Summary: Major depression is a highly prevalent, frequently debilitating illness that too often fails to respond to currently available treatments such as antidepressant medication. Furthermore, randomized controlled trials of antidepressants consistently demonstrate large placebo effects. The investigators hypothesize that individual differences in the function of key brain circuits underlie the observed variability in clinical responses to both placebo and antidepressant medication

2014 Clinical Trials

5286. Rivaroxaban in Thrombotic Antiphospholipid Syndrome

Criteria History of or condition associated with increased bleeding risk including, but not limited to: Major surgical procedure or trauma within 30 days before the randomization visit Clinically significant gastrointestinal bleeding within 6 months before the randomization visit History of intracranial, intraocular, spinal, or atraumatic intra-articular bleeding Chronic hemorrhagic disorder Known intracranial neoplasm, arteriovenous malformation, or aneurysm Planned invasive procedure with potential

2014 Clinical Trials

5287. A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body

, unstable angina pectoris, New York Heart Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension. Documented major electrocardiogram (ECG) abnormalities at the investigator's discretion. Major abnormalities documented by echocardiography with Doppler. Have significantly elevated brain natriuretic peptide (BNP) or elevated Troponin I at screening local laboratory tests. Predisposing conditions that are consistent with development of aneurysms of the ascending aorta

2014 Clinical Trials

5288. HeartMate PHPâ„¢ CE Mark Clinical Investigation Plan

(MAE) [ Time Frame: Post procedure or at hospital discharge (whichever is longer), 30 days post procedure ] Primary Safety Endpoint: Composite of Major Adverse Events (MAE): device-related cardiac death, new Q wave myocardial infarction, surgical intervention due to device complication or malfunction, device-related access site complication requiring intervention or device-related limb ischemia, cerebral vascular accident (CVA), new or worsening aortic valve insufficiency, major bleeding (...) that would preclude surgery, including aneurysms and significant tortuosity or calcifications Planned use of rotablator or atherectomy during the procedure Serum creatinine > 3.5mg/dL within 7 days of procedure Liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ 3x ULN or INR (Internationalized Normalized Ratio) ≥2 Uncorrectable abnormal coagulation parameters Active systemic infection requiring treatment with antibiotics Clinically relevant stroke or TIA within 3 months

2014 Clinical Trials

5289. CARE: A Prospective Multicenter Case Study to Assess Radiation Exposure in Patients Treated With the Penumbra Coil 400

relevant MeSH terms: Layout table for MeSH terms Aneurysm Intracranial Aneurysm Vascular Diseases Cardiovascular Diseases Intracranial Arterial Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases (...) review study of patients presenting with intracranial aneurysms who are treated with coil embolization therapy using the PC 400 or conventional coils. Data for each patient are collected acutely.Up to 90 patients treated with the PC 400 or conventional coils (2:1) at up to 15 centers in the USA will be enrolled. Condition or disease Intervention/treatment Intracranial Aneurysms Device: PC 400 Study Design Go to Layout table for study information Study Type : Observational [Patient Registry] Actual

2014 Clinical Trials

5290. Meditation for Dementia Caregivers Major Depressive Disorder in Family Dementia Caregivers

entering the calvarium; space occupying intracranial lesion; stroke/ aneurysm; Parkinson's or Huntington's disease; or Multiple Sclerosis. 4. Participants regularly practicing (≥ 2 times per week) any of the techniques utilized in the study to reduce stress: meditation, guided imagery, yoga. 5. Active suicidal plan, or suicide attempt within the past month. 6. Excessive use of alcohol, i.e., men whose alcohol consumption exceeds 14 standard drinks per week or 4 drinks per day, and women whose alcohol (...) by measuring brain activity, recording the pulse in order to determine variation in beat to beat intervals of the heart, and studying patterns of gene expression. Condition or disease Intervention/treatment Phase Central Meditation and Imagery Therapy Relaxation Recording Behavioral: Central Meditation and Imagery Therapy Behavioral: Relaxation cd Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 26 participants Allocation

2014 Clinical Trials

5291. The Neurophysiological Effects of Intravenous Alcohol as Potential Biomarkers of Ketamine's Rapid Antidepressant Effects in Major Depressive Disorder

stimulation (TMS) and vagal nerve stimulation (VNS), within 4 weeks of study phase II. Lifetime history of deep brain stimulation. Treatment with any disallowed concomitant medications. Positive HIV test Presence of ferromagnetic implants, e.g, heart pacemaker or aneurysm clip, or other contraindications to magnetic resonance imaging (MRI), e.g. claustrophobia or hearing loss. Clinically-significant anatomical brain abnormalities detected on routine brain MRI. Subjects who, in the investigator s judgment (...) : The primary hypothesis/outcome measure will be change in mean Montgomery-Asberg Depression Rating Scale (MADRS) total score from the pre-ketamine infusion baseline-to-7 days post-infusion between the FHP and FHN groups. Other exploratory measures include neurophysiological responses to intravenous alcohol infusion, brain neurochemical alterations during intravenous alcohol infusion, brain neurochemical alterations during intravenous ketamine infusion and resting state (task-free) functional magnetic

2014 Clinical Trials

5292. The Use of Cardiovascular Biomarkers in Abdominal Aortic Surgery

, 2014 Sponsor: Prim PD Dr Afshin Assadian Collaborator: Wilhelminenspital Vienna Information provided by (Responsible Party): Prim PD Dr Afshin Assadian, Wilhelminenspital Vienna Study Details Study Description Go to Brief Summary: The aim of the present study is the evaluation of cardiovascular biomarkers in patients with abdominal aortic aneurysms (AAA) or abdominal aortic occlusive disease AOD) undergoing open (OR) or endovascular aortic repair (EVAR) with regards to short- and long-term outcome (...) . By blood collection and measurement of the serum biomarkers Copeptin, N-terminal- pro Brain Natriuretic Peptide (NT-proBNP), cardiac Troponin I (cTnI), high sensitive Troponin T (hs-cTnT) and C-reactive Protein (CRP) we expect an improvement of patients stratification by assessment of cardiac stress tolerance. Data gathered may help to simplify the decision whether an open or endovascular approach for abdominal aortic repair (OR and EVAR) should be performed. Study Hypothesis: The evaluation

2014 Clinical Trials

5293. Tesamorelin Effects on Liver Fat and Histology in HIV

such as the presence of a pacemaker or cerebral aneurysm clip Previous weight loss surgery For women, positive pregnancy test performed in a CLIA certified laboratory using a test with a sensitivity of at least 25mIU/mL, or breastfeeding. Known hypersensitivity to tesamorelin or mannitol Unwillingness to abstain from the conception process during the study (i.e., must agree not to participate in an active attempt to become pregnant or impregnate, donate sperm, or participate in in vitro fertilization

2014 Clinical Trials

5294. Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease Participants

in the brain. In this study, healthy control participants and participants with AD will be studied. Information collected will include brain and plasma kinetics, tissue distribution (in the brain), radiation dosimetry, and test-retest variability of the signal in the brain. The study will consist of Part 1, Part 2A, and Part 2B. During Part 1, imaging data will be assessed on an ongoing basis and based on data, one tracer will be prioritized over the other two tracers. The tracer selected will be further (...) of [18F]RO6958948 injected will be Brain Scan [ Time Frame: Day 1 up to Day 14 ] Part 1: Standard Uptake Value Ratio (SUVR

2014 Clinical Trials

5295. Assessing The Effectiveness of a Preoperative High Intensity Interval Training Programme In Older Colorectal Cancer Patients

), Angina, Heart failure (class III/IV), Cardiac arrthymias, Right to left cardiac shunt, Recent cardiac event, Previous stroke/TIA, Aneurysm (large vessel or intracranial), Severe respiratory disease including pulmonary hypertension, COPD/asthma with an FEV1 less than 1.5 l, Coagulation disorders, Scarring disorders. Current neoadjuvant chemo/radiotherapy Inability to complete the consent process Involvement in invasive research study in previous 3 months. Contacts and Locations Go to Information from

2014 Clinical Trials

5296. Study on the Effect of Surgical Intestinal Manipulation

cases - blood sampling controles - blood sampling abdominal aortic aneurysm repair controls - blood sampling Other: blood sampling cases - blood sampling controles - blood sampling Outcome Measures Go to Primary Outcome Measures : subtypes of monocytes [ Time Frame: 1 day ] evaluate different subtypes of monocytes in brain-death donors by collecting portal and peripheral blood after lapaotomy and before dissection evaluate effect of intestinal manipulation [ Time Frame: 1 day ] evaluate the effect (...) information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: patients who are brain death patients who undergo an elective abdominal aortic aneurysm repair Exclusion Criteria: < 18 years of age Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2014 Clinical Trials

5297. Asia Africa Streptokinase Trial

: Patients with focal neurological deficits due to other cerebral pathology, such as intracerebral hemorrhage or neoplasm will be excluded Patients with rapidly resolving symptoms will be excluded, as will those with pre-existing functional deficits (mRS>2) or any history of intracranial bleeding. Recent (<3 months) surgical or ACS patients will be excluded Patients with known secured or unsecured cerebral aneurysms or arteriovenous malformations will not be eligible. Patients previously treated with SK (...) : Ashfaq Shuaib, Director Stroke Program, University of Alberta Identifier: Other Study ID Numbers: AASIST First Posted: May 30, 2014 Last Update Posted: December 30, 2014 Last Verified: December 2014 Keywords provided by Ashfaq Shuaib, University of Alberta: Thrombolysis Safety of Streptokinase tissue plasminogen activator tPA Stroke treatment Additional relevant MeSH terms: Layout table for MeSH terms Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases

2014 Clinical Trials

5298. Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI

, 2014 Last Update Posted : October 4, 2018 Sponsor: Uniformed Services University of the Health Sciences Collaborator: National Institutes of Health (NIH) Information provided by (Responsible Party): Ramon Diaz-Arrastia, Uniformed Services University of the Health Sciences Study Details Study Description Go to Brief Summary: Deficits in memory, attention, cognitive, and executive functions are the most common disabilities after traumatic brain injury (TBI). Dopamine (DA) neurotransmission (...) , which is under partial DA control, as a measure of dopaminergic activity on and off methylphenidate. Condition or disease Intervention/treatment Phase Traumatic Brain Injury Drug: methylphenidate Drug: Placebo Phase 2 Detailed Description: Males and females (n=30), between the ages of 18 and 55 years in the chronic stage after TBI who experience deficits in neuropsychological function from TBIs incurred 6 months after the injury, will be recruited from military treatment facilities or civilian

2014 Clinical Trials

5299. A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients

. Contraindication for MRI scanning (as assessed by local MRI safety questionnaire), which includes but is not limited to: a. Intracranial aneurysm clips (except Sugita^®; trademark owned by Mizuho Ikakogyo Co.Ltd. Tokyo) or other metallic objects; b. Intra- orbital metal fragments that have not been removed; c. Pacemakers or other implanted cardiac rhythm management/monitoring devices and non-MR conditional heart valves; d. Inner ear implants; and e. History of claustrophobia. For Heart Failure Subjects (Cohort

2014 Clinical Trials

5300. Effects of Transcranial Magnetic Stimulation (TMS) on Somatosensory Perception

(NCCIH) Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Center for Complementary and Integrative Health (NCCIH) ) Study Details Study Description Go to Brief Summary: Background: - Different parts of the brain are involved in feeling touch. Researchers want to study whether repetitive magnetic stimulation (rTMS) to the sensory cortex affects how sensation feels. rTMS is a repeated magnetic pulse that interferes with brain activity. It affects (...) a small part of the brain beneath the scalp. Researchers want to find out the role of sensory cortex in sensing different types of touch. Objectives: - To find out the role of sensory cortex, a brain area, in sensing different types of touch. Eligibility: - Healthy adults ages 18 45. Design: Participants will be pre-screened with a telephone interview. Then they will be screened with physical and psychological exams and a urine test. In Session 1, participants will have an MRI brain scan and fill out

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>